Clostridium infectious disease

Summary

Clostridium infectious disease (MONDO:0024388) is a disease and 17 clinical trials. Top therapeutic interventions include vancomycin, bezlotoxumab, and fidaxomicin. A subtype of gram-positive bacterial infections — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 17

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	Clostridium infectious disease
Mondo ID	MONDO:0024388
EFO	EFO:1000874
MeSH	D003015
SNOMED CT	56688005
Is cancer (heuristic)	no

Also known as: Clostridium infection · infection, Clostridium · infections, Clostridium

Disease family

This is a subtype of gram-positive bacterial infections. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › gram-positive bacterial infections › Clostridium infectious disease

Related subtypes (5): Erysipelothrix infectious disease, Actinomycetales infectious disease, Bacillaceae infectious disease, streptococcal infection, infection caused by Bifidobacterium

Subtypes (3): botulism, tetanus, infection due to clostridium perfringens

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

3 approved, 9 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Bezlotoxumab	Approved (phase 4)
Fecal Microbiota Spores, Live	Approved (phase 4)
Fidaxomicin	Approved (phase 4)
Amoxicillin	Phase 3 (in late-stage trials)
Cadazolid	Phase 3 (in late-stage trials)
Cefazolin	Phase 3 (in late-stage trials)
Clavulanic Acid	Phase 3 (in late-stage trials)
MK-3415	Phase 3 (in late-stage trials)
Nitazoxanide	Phase 3 (in late-stage trials)
Rifaximin	Phase 3 (in late-stage trials)
Surotomycin	Phase 3 (in late-stage trials)
Vancomycin	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Glutamine, Loperamide, Metronidazole, Misoprostol, PEGINTERFERON ALFA-2A, POLYETHYLENE GLYCOL 3350, Ridinilazole, Sodium Chloride.

Clinical trials & evidence

Clinical trials

Clinical trials: 17.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	5
Not specified	5
PHASE1	4
PHASE2	2
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05077085	PHASE4	WITHDRAWN	Bezlotoxumab Versus FMT for Multiple Recurrent CDI
NCT00269399	PHASE3	COMPLETED	A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)
NCT00314951	PHASE3	COMPLETED	Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018)
NCT00328263	PHASE3	COMPLETED	Efficacy and Safety of BIO-K + CL1285 in Prevention of Antibiotic-associated Diarrhea in Hospitalized Adult Patients
NCT00384527	PHASE3	TERMINATED	Study of Nitazoxanide in the Treatment of Clostridium Difficile-associated Disease
NCT00468728	PHASE3	COMPLETED	PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)
NCT00350298	PHASE2	COMPLETED	Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
NCT02563106	PHASE2	COMPLETED	A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI
NCT00127803	PHASE1	COMPLETED	Safety, Tolerability, and Immunogenicity Study of a Clostridium Difficile Toxoid Vaccine in Healthy Adult Volunteers
NCT00130221	PHASE1	COMPLETED	Skin Cleansing With Chlorhexidine to Decrease Hospital Acquired Infections
NCT00214461	PHASE1	COMPLETED	Safety, Tolerability, and Immunogenicity of a Clostridium Difficile Toxoid Vaccine in Healthy Elderly Volunteers
NCT04026009	PHASE1	COMPLETED	Safety and Immunogenicity Study of GSK’s Clostridium Difficile Vaccine 2904545A When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years
NCT00446355	Not specified	COMPLETED	Clinical Outcomes of Patients With Clostridium Difficile Associated Disease Attributable to Diverse tcdC Genotypes
NCT02681068	Not specified	UNKNOWN	MicroTrans - A Multicenter Registry of Fecal Microbiota Transplantation
NCT04179201	Not specified	UNKNOWN	Study on Clostridium Difficile Infection in Chinese Patients With Inflammatory Bowel Disease
NCT04874623	Not specified	COMPLETED	Monoclonal Antibodies in Clostridium Difficile Infection
NCT06277999	Not specified	COMPLETED	C.Difficile Observational Study

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
VANCOMYCIN	4	5
BEZLOTOXUMAB	4	2
FIDAXOMICIN	4	2
NITAZOXANIDE	4	1
RIFAXIMIN	4	1
LACTOBACILLUS ACIDOPHILUS	3	1
GS-CDA1	2	1
RIBAXAMASE	2	1
CHEMBL4299436	0	5